The xx medicinal products assessed in the field of oncological diseases include products for cell lung carcinoma, multiple myeloma, melanoma and many others. To date, the G-BA has concluded xx resolutions in this therapeutic area and evaluated a total of xx patient populations. When these subpopulations are weighted according to their patient share in the resolution, there is a major additional benefit for xx% of the populations and a considerable additional benefit for a further XX%. A minor additional benefit has been proved in XX% of the subpopulations, with the G-BA identifying a non-quantifiable additional benefit for XX% of the subpopulations.

The G-BA has seen no additional benefit proven for XX% of the subpopulations, with xx% receiving even less benefit than the comparative therapy. According to the G-BA, a total of xx% of the maximum xx million patients do not see any added value from the assessed medicinal product in relation to an appropriate comparative therapy.